Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Japanese Encephalitis Virus Vaccine»

Japanese Encephalitis Virus Vaccine
Japanese Encephalitis Virus Vaccine

Japanese Encephalitis Virus Vaccine

Pronunciation: en-se-fa-LI-tesClass: Viral vaccine

Trade Names:JE-Vax- Injection, lyophilized powder for suspension. Each mL contains mouse serum protein less than 50 ng, gelatin approximately 500 mcg, and formaldehyde less than 100 mcg

Trade Names:Ixario- Injection, suspension 6 mcg per 0.5 mL


Inactivated virus vaccine that induces neutralizing antibodies to Japanese encephalitis (JE) virus.



Immunity develops by 10th day after primary vaccination for JE-Vax and by the 7th day for Ixiaro .


Full duration of protection is unknown. A booster dose is recommended after 2 yr of primary series.

Indications and Usage

Active immunization for JE for persons 1 yr of age and older ( JE-Vax ) and for persons 17 yr of age and older ( Ixiaro ).


History of hypersensitivity to prior dose.


Hypersensitivity to thimerosal; hypersensitivity to proteins of rodent or neural origin.

Dosage and Administration


IM 2 doses of 0.5 mL IM 28 days apart. Complete immunization series at least 1 week prior to exposure to JE virus.

JE-VaxAdults and children 3 yr of age and older

Subcutaenously 3 doses of 1 mL subcutaneously on days 0, 7, and 30. The last dose should be given at least 10 days before exposure to JE virus. A booster dose of 1 mL may be given after 2 yr. Only under unusual circumstances, 2 doses may be given a week apart.

Children 1 to 3 yr of age

Subcutaenously 3 doses of 0.5 mL subcutaneously on days 0, 7, and 30. An abbreviated schedule of days 0, 7, and 14 may used because of time constraints. A booster dose of 0.5 mL may be given after 2 yr.

General Advice

  • Administer JE-Vax subcutaneously and Ixiaro by IM into the deltoid muscle. Do not administer IV or intradermally.
  • Before administering Ixiaro , shake the syringe well to obtain a white, opaque, homogenous suspension.
  • Do not mix with any other vaccine in the same syringe or vial.
  • Administer JE-Vax vaccine within 8 h after reconstitution.


Store vaccine between 35° and 46°F. Do not freeze. Use reconstituted JE-Vax within 8 h. During storage of Ixiaro , a clear liquid with a white precipitate can be observed.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions



Headache (28%); fatigue (11%), migraine (at least 1%).


Headache (15%).



Nausea (7%); diarrhea, vomiting (2%).



Angioedema of the extremities and face, especially of the lips and oropharynx; erythema multiforme; erythema nodosum; joint swelling; generalized itching.



Tenderness (36%); pain (33%); erythema (10%); induration (8%); edema; pruritus (4%).


Arm soreness and redness (25%); rash (5%).



Myalgia (16%); back pain (1%).



Nasopharyngitis (5%); pharyngolaryngeal pain, upper respiratory tract infection (2%); sinusitis (at least 1%); cough, rhinitis (1%).



Influenza-like illness (12%); pyrexia (3%); rash (1%).


Febrile episode (6%); flu-like symptoms (less than 5%).



Monitor patient for possible adverse reactions. Report suspected adverse reactions following immunization to the Vaccine Adverse Event Reporting System.


Category B ( Ixiaro ), Category C ( JE-Vax ).




Safety and efficacy not established in children younger than 1 yr of age ( JE-Vax ); safety and efficacy not established in children younger than 17 yr of age ( Ixiaro ).


Do not administer to patients with history of acute hypersensitivity to eggs or egg products; anaphylaxis may occur. Anaphylaxis also may occur in persons with no prior history of hypersensitivity to the vaccine components. Ensure that epinephrine injection (1:1,000) is always immediately available.

Immunosuppressed patients

Immunocompromised patients may have a diminished immune response.

Vaccine efficacy

The precise relationship between antibody level and efficacy has hot been established, even though these antibody titers persisted for at least 2 yr after immunization.



None reported.

Patient Information

  • Instruct patients to complete a 3-dose immunizing series for JE-Vax and a 2-dose immunizing series for Ixiaro , except in unusual circumstances.
  • Advise patients with a history of hives (following hymenoptera envenomation, drugs, physical or other provocation, or of idiopathic origin) that adverse reactions are more likely.
  • Inform patients that adverse reactions consisting of headache, rash, edema, and generalized urticaria or angioedema may occur shortly after vaccination or up to 17 days (usually within 10 days) following vaccination.
  • Advise patient or caregiver that injection-site reactions consisting of arm soreness and local redness may occur shortly after vaccination.
  • Advise patient or caregiver to use non–aspirin-containing OTC analgesics (eg, acetaminophen, ibuprofen) for fever, muscle aches, pain, or discomfort at injection site.
  • Inform patients that the vaccine may not fully protect everyone who receives the vaccine and to take precautions to avoid exposure to mosquito bites.

Copyright © 2009 Wolters Kluwer Health.